ReP USP - Resultado da busca

Filtros : "Mendes-Côrrea, Maria Cássia Jacintho" "MARTINELLI, ANA DE LOURDES CANDOLO" "FMRP" Limpar

Filtros

Collaboration
Normalized affiliation
- universidade federal de são paulo (unifesp) (~1)
Non normalized affiliation
- abbvie inc., north chicago, il (1)
- centro de orientacao e aconselhamento, secretaria municipal de saude (sms), pr (1)
- centro de referencia e treinamento em dst/aids, sp (1)
- centro de referência e treinamento dst/aids, são paulo (1)
- hospital federal dos servidores do estado do rio de janeiro (hfse), setor de gastro/hepatologia, rio de janeiro, rj (1)

Artigo de periodico
Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study (2017)
Callefi, Luciana Azevêdo; Villela-Nogueira, Cristiane Alves; Tenore, Simone de Barros; Carnaúba-Júnior, Dimas; Coelho, Henrique Sérgio Moraes; Pinto, Paulo de Tarso A.; Nabuco, Letícia Cancella; Pessôa, Mário Guimarães; Ferraz, Maria Lúcia Cardoso Gomes; Ferreira, Paulo Roberto Abrão; Martinelli, Ana de Lourdes Candolo; Chachá, Silvana Gama Florencio; Ferreira, Adalgisa de Souza Paiva; Bisio, Alessandra Porto de Macedo; Brandão-Mello, Carlos Eduardo; Álvares-da-Silva, Mário Reis; Reuter, Tania; Ivantes, Claudia Alexandra Pontes; Perez, Renata de Mello; Mendes-Côrrea, Maria Cássia Jacintho
Source: Clinics. Unidade: FMRP
Subjects: INIBIDORES DE ENZIMAS, HEPATITE C, DOENÇA CRÔNICA, ESTUDOS MULTICÊNTRICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CALLEFI, Luciana Azevêdo et al. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics, v. 72, n. 6, p. 378-385, 2017Tradução . . Disponível em: https://doi.org/10.6061/clinics/2017(06)08. Acesso em: 02 nov. 2024.
APA
Callefi, L. A., Villela-Nogueira, C. A., Tenore, S. de B., Carnaúba-Júnior, D., Coelho, H. S. M., Pinto, P. de T. A., et al. (2017). Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study. Clinics, 72( 6), 378-385. doi:10.6061/clinics/2017(06)08
NLM
Callefi LA, Villela-Nogueira CA, Tenore S de B, Carnaúba-Júnior D, Coelho HSM, Pinto P de TA, Nabuco LC, Pessôa MG, Ferraz MLCG, Ferreira PRA, Martinelli A de LC, Chachá SGF, Ferreira A de SP, Bisio AP de M, Brandão-Mello CE, Álvares-da-Silva MR, Reuter T, Ivantes CAP, Perez R de M, Mendes-Côrrea MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study [Internet]. Clinics. 2017 ; 72( 6): 378-385.[citado 2024 nov. 02 ] Available from: https://doi.org/10.6061/clinics/2017(06)08
Vancouver
Callefi LA, Villela-Nogueira CA, Tenore S de B, Carnaúba-Júnior D, Coelho HSM, Pinto P de TA, Nabuco LC, Pessôa MG, Ferraz MLCG, Ferreira PRA, Martinelli A de LC, Chachá SGF, Ferreira A de SP, Bisio AP de M, Brandão-Mello CE, Álvares-da-Silva MR, Reuter T, Ivantes CAP, Perez R de M, Mendes-Côrrea MCJ. Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study [Internet]. Clinics. 2017 ; 72( 6): 378-385.[citado 2024 nov. 02 ] Available from: https://doi.org/10.6061/clinics/2017(06)08
Trabalho de evento-resumo periodico
Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis (2016)
Pessoa, Mario G.; Ramalho, José Valdez Madruga; Alves, Katia; Cohen, Daniel E.; Nunes, Estevao Portela; Cheinquer, Hugo; Brandão-Mello, Carlos E.; Mendes-Côrrea, Maria Cássia Jacintho; Ferraz, Maria Lucia G.; Lari, Sara; Lui, Li; Tripathi, Rakesh; Pilot-Matias, Tami; Schulman, Nancy; Martinelli, Ana de Lourdes Candolo
Source: Hepatology. Conference titles: Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Unidades: FMRP, FM
Subjects: HEPATITE C, ANTIVIRAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PESSOA, Mario G. et al. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/hep.28800. Acesso em: 02 nov. 2024. , 2016
APA
Pessoa, M. G., Ramalho, J. V. M., Alves, K., Cohen, D. E., Nunes, E. P., Cheinquer, H., et al. (2016). Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis. Hepatology. Baltimore: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1002/hep.28800
NLM
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1002/hep.28800
Vancouver
Pessoa MG, Ramalho JVM, Alves K, Cohen DE, Nunes EP, Cheinquer H, Brandão-Mello CE, Mendes-Côrrea MCJ, Ferraz MLG, Lari S, Lui L, Tripathi R, Pilot-Matias T, Schulman N, Martinelli A de LC. Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis [Internet]. Hepatology. 2016 ; 64 949A-950A.[citado 2024 nov. 02 ] Available from: https://doi.org/10.1002/hep.28800

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024